The discovery of NOP58 as a key regulatory factor provides a new perspective on the biology of prostate cancer and highlights its potential as a prognostic biomarker and therapeutic target (Arriaga-Canon et al., 2018; Felgueiras et al., 2014). Here, NOP58 is linked to prostate carcinoma.